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Abstract: Chymotrypsin is a protease that is commonly used as a standard for protein crystallization
and as a model system for studying serine proteases. Unliganded bovine α-chymotrypsin was
crystallized at neutral pH using ammonium sulphate as the precipitant, resulting in crystals
that conform to P65 symmetry with unit cell parameters that have not been reported previously.
Inspection of crystallographic interfaces revealed that the major interface between any two molecules
in the crystal lattice represents the interface of the biological dimer, as previously observed for crystals
of unliganded α-chymotrypsin grown at low pH in space group P21.
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1. Introduction
Chymotrypsin is a serine endopeptidase secreted from the pancreas, and it is involved in
proteolytic digestion. Chymotrypsinogen A is activated via hydrolysis of the Arg15-Ile16 peptide
bond by trypsin to produce π-chymotrypsin. Autolytic cleavage of π-chymotrypsin at peptide bonds
13-14, 146-147, and 148-149 then follows to produce α-chymotrypsin, which consists of three separate
polypeptides cross-linked by five disulphide bonds [1]. Chymotrypsin was one of the first protein
structures solved by X-ray crystallography, and was the first solved structure of a protease [2].
Researchers quickly discovered that chymotrypsin can easily be crystallized using ammonium sulphate
as a precipitant, often with lower pH (<4.5), leading to crystal forms conforming to the space group
P21, while at higher pH (>4.5), crystal forms usually conform to the space group P42212, with the latter
crystal form primarily used for crystallization with a ligand. Since this discovery, a number of other
crystal forms have been reported. A summary of representative published crystal forms is presented
in Table S1. Given its long history of study and ease of purification, chymotrypsin has been used as a
model system for several purposes. Chymotrypsin is often used in combination with other proteins as a
control to study protein crystallization itself, such as probing general crystallization techniques as well
as general seeding techniques. In addition, many other proteases, such as the proteasome, elastases,
cathepsins, and calpain, have proven difficult to study in vitro due to problems in purification. As such,
chymotrypsin is often used as a model for studying ligand-protease interactions, especially with regard
to structure-guided drug design [3–5]. Here, we report a previously undocumented crystal form
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of α-chymotrypsin (Table 1) solved by X-ray crystallography to a resolution of 1.86 Å in the space
group P65.
Table 1. Macromolecule information.
Source Organism Bos taurus
Complete amino acid sequence of
chymotrypsinogen A (UniProt: P00766)
CGVPAIQPVL SGLSRIVNGE EAVPGSWPWQ VSLQDKTGFH FCGGSLINEN
WVVTAAHCGV TTSDVVVAGE FDQGSSSEKI QKLKIAKVFK NSKYNSLTIN
NDITLLKLST AASFSQTVSA VCLPSASDDF AAGTTCVTTG WGLTRYTNAN
TPDRLQQASL PLLSNTNCKK YWGTKIKDAM ICAGASGVSS CMGDSGGPLV
CKKNGAWTLV GIVSWGSSTC STSTPGVYAR VTALVNWVQQ TLAAN
2. Materials and Methods
2.1. Macromolecule Production
TLCK (Tosyl-L-lysyl-chloromethane hydrochloride)-treated α-chymotrypsin A isolated from
bovine pancreas was purchased from Worthington Biochemical Corporation (Lakewood, NJ, USA) as
a dialyzed (1 mM HCl), lyophilized powder (product code: CDTLCK) and dissolved in 0.1 M HEPES
pH 7.0 to a final concentration of 20 mg/ml.
Amino acids 14, 15, 147, and 148 (underlined) were removed during processing of
chymotrypsinogen A to produce α-chymotrypsin.
2.2. Crystallization
Protein was crystallized by vapour-diffusion using the hanging drop method at 16 ◦C.
Crystals formed as rods with a maximum dimension of approximately 400 µm after 1 month with
2 M ammonium sulphate as the reservoir solution. Complete details of the crystallization conditions
are given in Table 2. Prior to data collection, crystals were cryoprotected in Paratone-N (Hampton
Research) and flash cooled in liquid nitrogen.
Table 2. Crystallization.
Method Vapour Diffusion, Hanging Drop
Plate type 24-well tissue culture plate with glass cover slips sealed using vacuum grease
Temperature (K) 289
Protein concentration 20 mg/mL
Buffer composition of protein solution 0.1 M HEPES pH 7.0
Composition of reservoir solution 2 M (NH4)2SO4
Volume and ratio of drop 2 µL drop volume with 1:1 ratio of protein solution to reservoir solution
Volume of reservoir 0.5 mL
2.3. Data Collection and Processing
X-ray diffraction data were collected at 13000 eV from a single crystal using the MX1 beamline [6]
at the Australian Synchrotron. A total of 179 frames were collected at 1◦ intervals with 1◦ oscillation.
Data were processed using iMosflm (CCP4i, Oxford, UK) [7]. Data collection and processing statistics
are shown in Table 3.
Table 3. Data collection and processing. Values for the outer shell are given in parentheses. All data
were collected from a single crystal.
Diffraction Source Australian Synchrotron Beamline MX1
Wavelength (Å) 0.9537
Temperature (K) 100
Detector ADSC quantum 210r CCD
Crystal-detector distance (mm) 184.95
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Table 3. Cont.
Diffraction Source Australian Synchrotron Beamline MX1
Rotation range per image (◦) 1
Total rotation range (◦) 179
Exposure time per image (s) 1
Space group P65
a, b, c (Å) 126.8, 126.8, 122.0
α, β, γ (◦) 90, 90, 120
Mosaicity (◦) 0.53
Resolution range (Å) 29.55–1.86 (1.89–1.86)
Total No. of reflections 868057 (31308)
No. of unique reflections 93385 (4606)
Completeness (%) 100.0 (99.7)
Redundancy 9.3 (6.8)




Overall B factor from Wilson plot (Å2) 25.83
† Mean I/σ(I) falls below 2.0 at a resolution of 1.97 å. CC1/2 was used to inform resolution cut-off [8].
2.4. Structure Solution and Refinement
The structure of α-chymotrypsin was solved by molecular replacement using Phaser-MR [9] with
chain A of the 4Q2K (with all non-protein atoms removed) as the search model. The final solution
contained four copies of the search model in the asymmetric unit, with a translation function Z (TFZ)
score of 50.7, and log-likelihood gain (LLG) of 10450. Refinement of atomic coordinates was performed
by successive iterations of refinement using phenix.refine [10] and manual rebuilding in Coot [11].
Torsion-angle non-crystallographic symmetry (NCS) restraints were applied. Anisotropic refinement
of B-factors was restricted to torsion-liberation-screw (TLS) groups [12]. Both NCS and TLS groups
were defined automatically using phenix.refine. Optimization of the relative X-ray/stereochemistry
and X-ray/B-factor weights was performed in the final rounds of refinement. Refinement statistics are
shown in Table 4. The structure factors and atomic coordinates for the final model were deposited at
the Protein Data Bank (PDB) under accession 6DI8. Molecular graphic images were produced using
PyMOL (v2.0.7, Schrodinger, LLC, New York City, NY, USA) [13].
Table 4. Structure solution and refinement. Values for the outer shell are given in parentheses.
Resolution range (Å) 28.132–1.859 (1.925–1.859)
Completeness (%) 99.81 (99.63)
σ cutoff F > 0.0 σ(F)
No. of reflections, working set 93185 (8787)
No. of reflections, test set 4889 (468)
Final Rwork 0.1885 (0.3317)
Final Rfree 0.2252 (0.3416)
Cruickshank DPI (Å) 0.219








Average B factors (Å2)
Protein 33.1
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Most favoured (%) 97.45
Allowed (%) 2.13
3. Results and Discussion
The structure of bovine α-chymotrypsin was solved in space group P65 using data to 1.86 Å.
The unit cell parameters (Table 3) have not been reported previously for crystals of α-chymotrypsin
with this symmetry, indicating that this is a novel crystal form Residues 1 to 245 were confidently
modelled into the electron density, with the exceptions of Ser14, Arg15, Thr147, and Asn148, which were
removed during chymotrypsin activation and autolysis. The final model displays favourable geometric
statistics; the only Ramachandran outlier present in each molecule is Ile99 (electron density for Ile99
shown in Figure 1), which forms part of the S2 site and its conformation is well supported by strong
electron density. All five disulphide bonds are clearly observed in each subunit. The arrangement of
subunits is such that the N-terminal peptide (residues 1-13) is at the centre of the asymmetric unit, with
the active site facing out away from the centre. The asymmetric unit contains an arrangement of four
subunits of α-chymotrypsin exhibiting two-fold non-crystallographic rotational symmetry through
three mutually perpendicular axes (Figure 2).
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Figure 1. Reduced model bias map of resi Il i t y otrypsin structure solved in space
group P65. A composite omit map (2Fo-Fc, contoured at 1.5 σ) is displayed as blue mesh and proteins
are shown as yellow sticks.
Due to this being a new cr stal form, the crystallographic interfaces for this P65 structure
of unliganded α-chymotrypsin were analysed using PISA (Proteins, Interfaces, Structures and
Assemblies) [14] (http://www.ebi.ac.uk/pdbe/prot_int/pistart.html) and compared to the structure
of unliganded α-chymotrypsin solved in spacegroup P21 (PDB ID: 4CHA), which contains two
chymotrypsin molecules in the asymmetric unit [15]. Table 5 details the interfaces for α-chymotrypsin
solved in spacegroup P65. Interfaces for the P21 structure are listed in Table S2. Overall, 77% of
interface residues for the P65 crystal form are at interfaces in the P21 structure. Interface 1 is largely
conserved in each of the structures, involving 11 hydrogen bonds and 1 salt bridge, and is formed
between molecules of the asymmetric unit of the P21 structure, but between symmetry-mates of our P65
crystal (Figure 3). This is the dimerization interface of α-chymotrypsin, which is formed by the active
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site face of each monomer [15,16]. Thus, the tetramer asymmetric unit observed in P65 contains four
subunits; each individual subunit forms a biological assembly (dimer) with crystallographic symmetry
mates. Interface 2 also consists of the same residues for the P65 and P21 forms. Multiple bonding
interactions are observed at this interface for the P65 crystal form, with 10 hydrogen bonds and 2 salt
bridges identified. For the P21 crystal form, however, only a single salt bridge is present. This is
consistent with tighter packing at the central interfaces of the P65 crystal form. Although most of
the residues involved in interface formation are shared between these structures, interfaces 3–6 were
not conserved, due to the evident difference in crystal packing. The residues forming each of these
interfaces in space group P65 were shared across several interfaces of the P21 crystal form.Crystals 2018, 8, x 5 of 7 
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Table 5. Crystallographic interfaces for unliganded α-chymotrypsin in space group P65. 
Interface # Symmetry Operation Interface Area (Å2) Subunits† 
1 X-Y, X+1, Z-1/6 1049 B, C 
 X-Y, X, Z-1/6 1038 A, D 
2 X, Y, Z 668 D, B 
Figure 2. Asym etric unit of bovine α-c sin crystallized in space group P65 (P B I : 6DI8).
The four chymotrypsin olec les are coloure differently and shown in cartoon representation.
The view is down one axis of two-fold non-crystallographic symmetry; the other two perpendicular
axes are shown as black bars. The nucleophilic serines (Ser195) at the catalytic site are shown as sticks.
N- and C-termini are labelled.
Table 5. Crystallographic interfaces for unliganded α-chymotrypsin in space group P65.
Interface # Symmetry Operation Interface Area (Å2) Subunits †
1 X-Y, X+1, Z-1/6 1049 B, C
X-Y, X, Z-1/6 1038 A, D
2 X, Y, Z 668 D, B
X, Y, Z 625 C, A
3 X, Y, Z 562 D, A
X, Y, Z 539 C, B
4 X, Y, Z 344 B, A
X, Y, Z 340 D, C
5 -X-1, -Y, Z-1/2 361 A, C
-X-1, -Y, Z-1/2 218 B, D
6 -X-1, -Y, Z-1/2 145 A, D
-X-1, -Y, Z-1/2 136 B, C
† Subunits A–D constitute the asymmetric unit. Each subunit is composed of three separ te polypeptide chai s,
crosslinked by disulphide bonds.
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Figure 3. The major interface (“interface 1”—see text) present in the crystal lattice is conserved between
α-chymotrypsin crystallized in space group P65 and in P21. (A) A single chymotrypsin molecule of
the asymmetric unit of the P65 crystal form is shown in cartoon representation coloured green; the
symmetry mate is coloured grey. Interfacing residues are shown as sticks; catalytic residues (His57,
Asp102 and Ser195) are coloured red. (B) The asymmetric unit of α-chymotrypsin crystallized in P21
(PDB ID: 4CHA).
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